Deucravacitinib by Bristol-Myers Squibb can help with psoriasis, psoriatic arthritis, Crohn’s disease, ulcerative colitis, lupus nephritis, and systemic lupus erythematosus.
Mavacamten by Bristol-Myers Squibb is a new breath for all patients with obstructive hypertrophic cardiomyopathy.
Oral ozanimod will provide clinical remission of ulcerative colitis for a third of patients.
Ponesimod is a new drug that changes the course of multiple sclerosis and is a direct competitor to Gilenya (fingolidoma), Mayzent (siponimod), and Zeposia (ozanimod).
Bristol-Myers Squibb has come up with ozanimod, a direct competitor to Novartis’ fingolimod and siponimod, for the treatment of multiple sclerosis.